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BACKGROUND: Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only. Its cytotoxicity is
enhanced by folinic acid (FA) and interferon-a (INFa). In this trial, the effects of FA and IFNa on adjuvant 5-FU chemoradiotherapy
in locally advanced rectal cancer were investigated.
METHODS: Patients with R0-resected rectal cancer (UICC stage II and III) were stratified and randomised to a 12-month adjuvant
chemoradiotherapy with 5-FU, 5-FUþFA, or 5-FUþIFNa. All patients received levamisol and local irradiation with 50.4Gy.
RESULTS: Median follow-up was 4.9 years (n¼796). Toxicities (WHO IIIþIV) were observed in 32, 28, and 58% of patients receiving
5-FU, 5-FUþFA, and 5-FUþIFNa, respectively. No differences between the groups were observed for local or distant recurrence.
Five-year overall survival (OS) rates were 60.3% (95% confidence interval (CI): 54.3–65.8), 60.4% (54.4–65.8), and 59.9%
(53.0–66.1) for 5-FU, 5-FUþFA, and 5-FUþIFNa, respectively. A subgroup analysis in stage II (pT3/4pN0) disease (n¼271)
revealed that the addition of FA tended to reduce the 5-year local recurrence (LR) rate by 55% and increase recurrence-free survival
and OS rates by 12 and 13%, respectively, relative to 5-FU alone.
CONCLUSIONS: Interferon-a cannot be recommended for adjuvant chemoradiotherapy of rectal cancer. In UICC stage II disease, the
addition of FA tended to lower LR and increased survival. The addition of FA to 5-FU may be an effective option for adjuvant
chemoradiotherapy of UICC stage II rectal cancer.
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During the last two decades, treatment strategies of rectal cancer
have improved markedly. Although in the early 1990s local
recurrence (LR) rates beyond 20% and overall recurrence rates
beyond 50% were reported for UICC stage II and III (Gastro-
intestinal Tumor Study Group, 1985; Fisher et al, 1988; Krook et al,
1991), multimodal approaches were shown to increase local
control and survival (Swedish Rectal Cancer Trial, 1997; Wolmark
et al, 2000). In parallel, total mesorectal excision (TME), including
the complete removal of the fatty tissue and lymph nodes
surrounding the rectum, was introduced resulting in a significant
improvement of local control (Martling et al, 2000; Wibe et al,
2002). Local recurrence rates were further decreased in locally
advanced rectal cancer using neoadjuvant strategies compared
with the adjuvant setting (Sauer et al, 2004) or combining
radiation with chemotherapy (Bosset et al, 2006; Ge ´rard et al,
2006). In contrast to the old resection technique (Swedish Rectal
Cancer Trial, 1997), the addition of neoadjuvant radiation to
modern TME surgery reduced LR, but did not improve survival
(Peeters et al, 2007).
Irrespective of pre- or postoperative (chemo)radiation, distant
metastases still occur in about 40% of locally advanced rectal
cancers (Swedish Rectal Cancer Trial, 1997; Wolmark et al, 2000;
Tepper et al, 2002; Sauer et al, 2004; Peeters et al, 2007). In order to
improve prognosis, systemic treatment of these patients has to be
optimised (Weiss et al, 2009). Marked advances in adjuvant
treatment have been achieved in colon cancer during the last two
decades (IMPACT investigators, 1995; Porschen et al, 2001; Haller
et al, 2005; Link et al, 2005; Kuebler et al, 2007; Andre ´ et al, 2009).
Despite the clear benefit of 5-fluorouracil (5-FU) modulation by
folinic acid (FA) in colon cancer (IMPACT investigators, 1995;
Porschen et al, 2001; Haller et al, 2005; Link et al, 2005), a clear
benefit of this combination in rectal cancer could not be shown
(QUASAR Collaborative Group, 2000; Wolmark et al, 2000; Tepper
et al, 2002; Dahl et al, 2009). Standard chemoradiotherapy of rectal
cancer (UICC stage II and III) is often still carried out using 5-FU
monotherapy (de Gramont and Haller, 2008).
5-Fluorouracil toxicity is modulated by FA and interferon-a
(IFNa) (Corfu-A Study Group, 1995; Van Triest et al, 2000).
Among several other mechanisms, FA increases the concentration
of the cofactor 5,10-methylenetetrahydrofolate, thereby stabilising
the ternary complex formation of 5-fluoro-20-deoxyuridine-
50-monophosphate, with thymidylate synthase inhibiting DNA
synthesis (Van Triest et al, 2000), whereas INFa enhances 5-FU
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smetabolism and, moreover, has immunomodulating and anti-
angiogenic effects (Makower and Wadler, 1999; Slaton et al, 1999).
The aim of this trial was to improve adjuvant chemoradiotherapy
of rectal cancer by modulating 5-FU with either FA or IFNa.
Secondary aims were to characterise toxicity of the regimens
and identify clinical and pathological parameters influencing
recurrence and prognosis.
PATIENTS AND METHODS
Ethics
The German ‘Research Group Oncology of Gastrointestinal
Tumors’ (FOGT) designed a prospective randomised trial
(FOGT-2) to optimise adjuvant treatment of rectal cancer conform
to GCP/ICH rules and respecting the Helsinki Declaration (1989)
to improve adjuvant treatment of locally advanced rectal cancer.
It was approved by the Ethics Committee of the University of Ulm
No. 87/91) and supervised by an independent study monitor.
A similarly designed trial (FOGT-1) was performed in colon cancer
(Link et al, 2005).
Patient eligibility criteria
Patients had a medical history, physical examination, ECG,
colonoscopy, complete blood cell count, and chemistry, including
liver and renal function parameters and carcinoembryonic antigen.
Distant metastases were excluded by abdominal ultrasound, chest
X-ray, and intraoperative liver palpation. Computed tomography
or MRI scans were optional.
Eligibility was defined as potentially curative en bloc resection
(R0) of an adenocarcinoma of the rectum with a lower tumour edge
within 12cm from the anal verge determined by rectoscopy, a
pathological UICC stage II (pT3/4pN0M0) or III (pT1-4pNposM0)
with examination of at least 12 lymph nodes, a white blood count
X3500ml
 1, a platelet count X100000ml
 1, a ECOG performance
status of 0 or 1, and written informed consent. Ineligible were
patients not fulfilling these criteria or having a history of cancer,
except for adequately treated superficial basal or squamous cell skin
cancer or in situ carcinoma of the cervix, getting previous radio- or
chemotherapy, pregnant or nursing women, others having severe
concomitant diseases limiting life expectancy or not allowing chemo-
therapy, and with social conditions not allowing a 5-year follow-up.
Surgical procedures
Anterior resections (AR) including Hartmann procedures and
abdominoperineal resections (APR) had to be performed accord-
ing to the recommendations of the German Cancer Society
(Herfahrt and Schlag, 1991). A distal free resection margin of
3cm was required for ARs and a wide resection of the levators
close to the pelvis wall in case of APRs.
Pathological evaluation
The fourth version of the UICC/TNM classification was used to
document the pathological staging. Results in this paper are
reported according to the sixth version. Overall, 57 patients
initially documented as pN3 (central positive lymph nodes, fourth
version) were summarised with the group of pN2. R0 was defined
as complete resection to all directions without limit (0mm). CRM
was not recorded. No central pathological review was performed.
Stratification and randomisation procedures
Randomisation was performed during a phone call according to an
allocation sequence generated by the Institute of Biometrics of the
University of Ulm. Patients were stratified according to the centre,
pT (pT1/2 vs pT3/4), and lymph node status (pN0 vs pN1 vs pN2).
Chemotherapy
At the time of the trial design, systemic adjuvant therapy of rectal
cancer was carried out analogous to the recommended standard in
colon cancer, consisting of 5-FU and oral levamisol for 12 months
(NIH Consensus Conference, 1990). Therapy was scheduled
to begin 14 days after surgery. All patients received 5-FU and
levamisol. Levamisol (50mg) was given orally three times on
3 consecutive days every 2 weeks (days 1–3). 5-Fluorouracil
(450mgm
 2) was administered as infusion for 60–120min on
days 1–5. At 28 days after this loading course, 5-FU was given once
weekly for 48 weeks and, if tolerated well, increased to 500mgm
 2.
During irradiation, 5-FU was reduced to 80%. Folinic acid
(200mgm
 2, Rescuvolin, Medac GmbH, Hamburg, Germany)
was given as a short infusion (10min) before 5-FU. Interferon-a
(Roferon, Roche, Grenzach-Wyhlen, Germany) treatment con-
sisted of 6 10
6IU as subcutaneous self-injection 3  weekly.
Training of self-injection was initiated on day 28.
Radiation
Radiotherapy consisted of 50.4Gy (45Gy with 5.4Gy small volume
boost) delivered in fractions of 1.8Gy 5  weekly starting 6–8
weeks after surgery and was carried out lying face down and using
a three-field technique. The target volume included the primary
tumour and its mesentery with vascular supply containing the
peri-rectal, pre-sacral, and internal iliac nodes. The upper limit
was the L5/S1 junction, the dorsal limit the outer face of the
sacrum/coccygis, the ventral limit the inner bone of the os pubis,
and the lower limit at least 3cm below the anastomosis in case of
AR, and including the perineum in case of APR.
Toxicity
Toxicity was evaluated according to the WHO criteria. Follow-up
during adjuvant treatment as well as dose-reduction procedures in
case of grade III or IV toxicities were described (Link et al, 2005).
Severe toxicities were reported to the German drug authority
‘BfArM’.
Follow-up
Follow-up was performed 4-monthly for 2 years and 6-monthly for
3 years, including history, physical examination, white blood
count, liver and renal function, and carcinoembryonic antigen.
Computed tomography of the pelvis, abdominal ultrasound, and
chest X-ray were performed annually, and colonoscopy biannually.
Additional annual follow-up exceeding 5 years was optional.
Statistical analysis and end points
The primary objective was to improve adjuvant 5-FU chemor-
adiotherapy. Our hypothesis was that modulation of 5-FU by
addition of either FA or INFa may increase overall survival (OS).
For sample size estimation, the following assumptions
were made: the 5-year OS rate of 5-FU was estimated to be 58%
(Krook et al, 1991). If the 5-year OS rate for one of the additives is
10% points higher compared with 5-FU, the study has 80% power
to detect superiority at a level of significance of 5% (one-sided),
with a sample size of 280 subjects per group. 5-Fluorouracil alone
was compared with 5-FU with the addition of FA and INFa. Owing
to the fact that the INFa arm was closed in 1999 (see Results),
a confirmatory comparison was only carried out for 5-FU alone vs
5-FUþFA (log-rank test).
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sPrimary end point of the study was OS. Overall survival was
compared by log-rank testing for 5-FU alone and 5-FUþFA.
Secondary end points were recurrence-free survival (RFS), LR,
toxicity, and treatment compliance. Overall survival was computed
from the start of chemotherapy until death of any cause (events)
or until the last observation date (censored observations).
Recurrence-free survival was defined as time from the start of
chemotherapy until diagnosis of any tumour recurrence or
tumour-related death (events) or until death due to other reasons
or last observation date (censored observations). Local recurrence
was defined as time from the start of chemotherapy to diagnosis of
local tumour recurrence (events) or death, last observation date, or
sole occurrence of distant metastases (censored observations).
Survival curves were generated by the Kaplan–Meier method.
Five-year survival rates are shown in % with 95% confidence
intervals. Toxicity rates were compared between the treatment
arms using the w
2 test. Stratified Kaplan–Meier analyses were
performed to detect variables influencing LR, RFS, and OS, and
compared with the log-rank test. All these tests were used for
exploratory data analysis. Statistical analysis was performed using
SAS version 9.1 (SAS Institute Inc., Carry, NC, USA).
RESULTS
Patient and tumour characteristics
A total of 863 patients from 55 hospitals were enrolled. Of these, 67
(7.8%) were regarded as drop-outs (Figure 1). Clinical and
pathological characteristics of the remaining 796 patients are
summarised in Table 1.
Adjuvant treatment and compliance
Treatment was started on 29 July 1992 for the first patient and
finished on 6 March 2003 for the last patient. All 796 patients
received 5-FU chemotherapy (Figure 1). Four patients randomised
to 5-FU alone received additional FA and four randomised
to 5-FUþFA received only 5-FU (Figure 1). Self-injection
of INFa was refused by 30 patients (Figure 1). In total, 11 received
the 5-FU loading course and discontinued any further adjuvant
therapy. In all, 19 continued adjuvant treatment without INFa,
of these seven received 5-FU alone and 12 asked to receive
5-FUþFA.
The administration of the complete 12-month course of
adjuvant chemoradiotherapy was documented for 50.3% (400 out
of 796) of the patients, 50.4% (142 out of 282), 53.3% (155 out of
291), and 46.2% (103 out of 223) of the 5-FU, 5-FUþFA, and
5-FUþINFa group, respectively (Figure 1, Table 2). At least
6 months were given to 67.7% (539 out of 796). Discontinuation
was observed in 10.8% (n¼86) within the first, 9.5% (n¼76)
within the second, 6.7% (n¼53) within the third, and 10.8%
(n¼86) within the fourth quarter. No data about the duration of
chemotherapy were available for 95 patients. Reasons for
discontinuation of chemotherapy are shown in Table 2.
For patients discontinuing chemotherapy within the first quarter
of treatment (n¼86), radiation was not administered in
Assessed for eligibility and
randomly assigned (n = 863)
Excluded (n = 67)
Not meeting inclusion criteria (n = 30)
Postoperative complications (n = 24)
Refused to participate (n = 7)
Other reasons (n = 6)
Patients randomly assigned and
eligible (n = 796)
Allocated to
5-FU + FA + INFα
n = 282 n = 291 n = 223
Received
Did not receive
Excluded from analysis
Discontinued treatment
n = 278
n = 4
n = 0
n =102
n = 287
n = 4
n = 0
n = 101
n = 193
n = 30
n = 0
n = 95
Analysed
Excluded from analysis
n = 282
n = 0
n = 291
n = 0
n = 223
n = 0
Figure 1 CONSORT diagram.
Table 1 Clinical and pathological characteristics
Treatment
Patients
Number
5-FU
(N¼282)
5-FU+FA
(N¼291)
5-FU+IFNa
(N¼223)
Total
(N¼796)
Age (years)
Median 61.6 61.4 61.2 61.4
Range 31.5–81.4 23.0–81.4 29.6–86.3 23.0–86.3
Sex
Male 180 191 140 511
Female 102 100 83 285
Type of resection
a
AR
b 135 126 98 359
APR 60 78 50 188
Unknown 87 87 75 249
UICC stage
II 93 97 81 271
A T3 N0 85 89 71 245
BT 4N 0 8 8 1 0 2 6
III 189 194 142 525
A T1/2 N1 26 25 20 71
B T3/4 N1 76 87 64 227
C T1–4 N2 87 82 58 227
Tumour depth (T)
13 2 4 9
23 3 3 5 1 8 8 6
3 225 227 182 634
42 1 2 7 1 9 6 7
Lymph nodes (N)
0 93 97 81 271
1 102 112 84 298
2 87 82 58 227
Grading (G)
1+2 212 219 174 605
3 55 61 42 158
Unknown 15 11 7 33
Abbreviations: AR¼anterior resections; APR¼abdominoperineal resections;
FA¼folinic acid; 5-FU¼5-fluorouracil; IFNa¼interferon-a; UICC¼International
Union Against Cancer.
aType of resection was determined retrospectively.
bIncluding Hartmann procedures (5-FU, n¼3; 5-FU+FA, n¼3; 5-FU+INFa, n¼3;
total, n¼9).
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on radiation were available in 27 patients.
Toxicity
Toxicity data were available for 685 patients (86%). World Health
Organisation III and IV toxicities occurred in 37.5% (257 out of
685) of the patients. Despite the fact that 30 of 223 patients (13.5%)
never received INFa, toxicities occurred in more patients (58.1%)
receiving 5-FUþINFa than 5-FU (31.5%) and 5-FUþFA (27.7%)
attributable to more frequent haematological, gastrointestinal, and
neurological courses (Po0.001; Table 3). Toxicity-related abrup-
tion (23 out of 223, 10.3%) was also higher in comparison to 5-FU
(14 out of 282, 5.0%) and 5-FUþFA (nine out of 291, 3.1%). This
prompted the study review committee to close the INFa arm in
February 1999.
Three deaths due to treatment-related toxicity were documen-
ted. One patient receiving 5-FU immediately died after the loading
course owing to severe febrile neutropenia followed by pneumonia.
Another patient receiving 5-FUþINFa died in month 7 of
treatment owing to diarrhoea with massive dehydration and renal
failure. The third patient (5-FU) died 6 months after completing
chemoradiotherapy owing to infectious complications caused by
fistulas in the pelvis without evidence of LR.
Tumour recurrence
The median follow-up was 4.9 years (range: 0.0–16.7 years). In all,
349 recurrences have been reported resulting in a recurrence rate
of 43.8% (Table 4). Recurrence was reported in seven patients after
5 years of follow-up.
Local recurrence was reported for 100 patients (12.6%), of which
45 patients of this group had both local and distant relapse.
Treatment did not influence LR in stage III. In contrast, addition of
FA reduced 5-year LR rate by 55% in stage II disease compared
with 5-FU (Table 5). In stage II, IIIa, IIIb, and IIIc, 11.4% (31 out of
271), 11.3% (8 out of 71), 11.9% (27 out of 227), and 15.0% (34 out
of 227) had LR, respectively. Patients with grading 1þ2 and 3 had
LR in 11.2% (68 out of 605) and 15.8% (25 out of 158), respectively,
and patients undergoing AR and APR in 11.4% (41 out of 359) and
15.4% (29 out of 188), respectively. The cumulative frequency of
LR with respect to adjuvant treatment in UICC stage II, UICC
substage, grading, and resection type are summarised in Table 5
and plotted in Figure 2.
Distant metastases were reported in 284 patients (35.7%). The
addition of FA tended to increase 5-year RFS in stage II, but not in
stage III disease (Table 5). Recurrence-free survival was associated
with UICC substage, tumour grading, and resection type (Table 5).
Kaplan–Meier curves of RFS are shown in Figure 3.
Survival
As of November 2009, 335 patients (42.1%) died, 43.3% of the
patients (122 out of 282) receiving 5-FU, 40.9% of the patients (119
out of 291) receiving 5-FUþFA, and 42.2% of the patients (94 out
of 223) receiving 5-FUþINFa. Disease-specific (disease-related)
deaths occurred in 36.2% of the patients with 5-FU (102 out of
282), in 33.7% of the patients with 5-FUþFA (98 out of 291), and
in 33.6% of the patients receiving with 5-FUþINFa (75 out of
223), combining to a total disease-specific death rate of 82.1% (275
out of 335). A total of 43 patients (12.8%) died of other reasons,
including the three patients with treatment-related toxicity,
whereas the cause of death was unknown in 17 patients.
Table 2 Reasons for treatment discontinuation
Treatment
5-FU
(N¼282)
5-FU+FA
(N¼291)
5-FU+IFNa
(N¼223)
Total
(N¼796)
Patient’s demand 33 45 32 110
Toxicity 14 9 23 46
Disease progression 45 34 29 108
Secondary tumour 2 1 1 4
Death 3 3 2 8
Other reasons 3 4 6 13
Missing information 2 5 2 9
Total (in %) 102 (36) 101 (35) 95 (43) 298 (37)
Abbreviations: FA¼folinic acid; 5-FU¼5-fluorouracil; IFNa¼interferon-a.
Table 3 Toxicities WHO III+IV
Treatment
5-FU
(N¼282)
5-FU+FA
(N¼291)
5-FU+INFa
(N¼223)
Total
(N¼796)
Toxicity data available
a N¼241 N¼253 N¼191 N¼685
Haematological
b 13 6 48 67
Nausea/vomiting 7 12 20 39
Diarrhoea 38 41 53 132
Fever 1 3 13 17
Skin 18 16 23 57
Neurological 4 6 13 23
Others
c 12 19 20 51
No cause stated 73 67 107 247
Caused by
Chemotherapy 35 31 56 122
Radiotherapy 19 22 7 48
Both 22 17 48 87
Number of patients
d
(in %)
76 (32) 70 (28) 111 (58) 257 (38)
Abbreviations: FA¼folinic acid; 5-FU¼5-fluorouracil; IFNa¼interferon-a; WHO¼
World Health Organisation.
aThe results of toxicity were based on the analysis of 685
patients for whom toxicity data were available.
bNumber of documented toxicities
4WHO II.
cIncluding obstipation and infections, as well as renal, pulmonal, and
cardiac toxicity.
dTotal number of patients affected by any toxicity 4WHO II.
Table 4 Localisation and frequency of tumour recurrence
Treatment
5-FU
(N¼282)
5-FU+FA
(N¼291)
5-FU+INFa
(N¼223)
Total
(N¼796)
Total number of patients 129 123 97 349
Recurrence rate (in %) 45.7 42.3 43.5 43.8
Local recurrence (only) (in %) 21 (7.4) 16 (5.5) 18 (8.1) 55 (6.9)
Local and distant recurrence
(in %)
18 (6.4) 15 (5.2) 12 (5.4) 45 (5.7)
Distant recurrence (only)
(in %)
88 (31.2) 88 (30.2) 63 (28.3) 239 (30.0)
Unknown localisation (in %) 2 (0.7) 4 (1.4) 4 (1.8) 10 (1.3)
Distant metastases (events)
a
Liver 60 54 42 156
Lung 41 35 25 101
Peritoneum 16 8 8 32
Bone 2 11 4 17
Other locations 23 22 17 62
Abbreviations: FA¼folinic acid; 5-FU¼5-fluorouracil; IFNa¼interferon-a.
aOwing
to the fact that some patients showed more than one location of distant metastases,
the total number of distant metastases is higher than the patient number.
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Five-year rates
Risk groups No. LR in % (95% CI) RFS in % (95% CI) OS in % (95% CI)
Treatment
5-FU 282 16.7 (12.3–22.5) 54.4 (48.2–60.1) 60.3 (54.3–65.8)
5-FU+FA 291 13.6 (9.6–19.0) 58.0 (51.9–63.6) 60.4 (54.4–65.8)
5-FU+INFa 223 17.1 (12.2–23.8) 56.5 (49.5–63.0) 59.9 (53.0–66.1)
Treatment of UICC II
5-FU 93 16.1 (9.6–26.1) 68.4 (57.8–76.8) 72.7 (62.3–80.6)
5-FU+FA 97 7.2 (3.3–15.5) 76.7 (66.8–84.0) 82.1 (72.8–88.5)
5-FU+INFa 81 14.6 (8.1–25.5) 67.3 (55.8–76.5) 76.1 (65.1–84.0)
Treatment of UICC III
5-FU 189 17.0 (11.5–24.7) 47.2 (39.6–54.3) 54.2 (46.7–61.1)
5-FU+FA 194 17.5 (11.9–25.2) 48.1 (40.6–55.2) 49.4 (42.0–56.4)
5-FU+INFa 142 18.7 (12.2–28.1) 49.8 (40.8–58.2) 50.5 (41.8–58.6)
UICC stage
II (pT3–4 pN0) 271 12.4 (8.8–17.4) 71.0 (65.1–76.1) 77.1 (71.5–81.7)
IIIa (pT1–2 pN1) 71 12.6 (6.2–24.8) 64.0 (51.2–74.3) 66.5 (54.0–76.3)
IIIb (pT3–4 pN1) 227 16.1 (11.2–22.7) 53.2 (46.1–59.7) 57.6 (50.7–63.9)
IIIc (pT1–4 pN2) 227 21.4 (15.4–29.3) 38.3 (31.7–44.8) 40.7 (34.2–47.1)
Tumour grading
G1+2 605 14.1 (11.2–17.6) 59.2 (55.0–63.1) 63.9 (59.8–67.6)
G3 158 21.9 (15.0–31.4) 45.0 (36.7–53.0) 46.7 (38.6–54.3)
Type of resection
AR 359 12.9 (9.5–17.4) 60.4 (55.0–65.4) 65.3 (60.1–70.1)
APR 188 21.1 (14.9–29.3) 46.2 (38.6–53.5) 50.8 (43.3–57.8)
Unknown 249 16.2 (11.6–22.5) 57.8 (51.1–63.8) 59.8 (53.4–65.7)
Abbreviations: AR¼anterior resections, including Hartmann procedures (n¼9; APR¼abdominoperineal resections; CI¼confidence interval; FA¼folinic acid;
5-FU¼5-fluorouracil; IFNa¼interferon-a;L R¼local recurrence; OS¼overall survival; RFS¼recurrence-free survival; UICC¼International Union Against Cancer.
Stage II Substage
IIIc
P=0.039 P=0.265
50
40
30
20
10
0
F
r
e
q
u
e
n
c
y
 
o
f
 
L
R
 
(
%
)
F
r
e
q
u
e
n
c
y
 
o
f
 
L
R
 
(
%
)
F
r
e
q
u
e
n
c
y
 
o
f
 
L
R
 
(
%
)
Time (years)
Time (years) Time (years)
No. at risk
5-FU
+FA
5-FU
II
+INFα
50
40
30
20
10
0
Time (years)
IIIa
IIIb
No. at risk
UICC II
5-FU+FA
5-FU+INFα
97 87 81 77 71 44 18 IIIb
IIIa
IIIc
Grading
G3
Resection type
P=0.105 P=0.022 50
40
20
30
10
0
F
r
e
q
u
e
n
c
y
 
o
f
 
L
R
 
(
%
)
50
40
20
30
10
0
G3
G1+2
UNK
APR
AR
No. at risk No. at risk
G1+2
G3
AR
UNK
APR
0 6 5 4 3 2 1
06 5 4 3 2 1 06 5 4 3 2 1
06 5 4 3 2 1
81 15 34 53 59 62 74
93 19 41 62 63 68 80
227 15 48 79 95 113 155
227 27 67 108 119 134 181
71 18 34 44 45 50 59
199 271 52 119 186 211 241
158 16 38 64 72 86 113
605 92 220 337 370 406 500 359 66 134 209 227 246 302
249 25 84 130 141 160 197
188 21 50 78 90 102 137
Figure 2 Cumulative frequency of local recurrence (LR): (A) LR in UICC stage II (pT3/4pN0) according to treatment; (B) LR according to UICC stage II
(pT3/4pN0), and substages IIIa (pT1/2pN1), IIIb (pT3/4pN1), and IIIc (pT1-4pN2); (C) LR according to tumour grading; and (D) LR according to the type of
resection: anterior resection (AR), abdominoperineal resection (APR), and resection type unknown (UNK). AR included nine Hartmann procedures.
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(78.3%) compared with 5-FU (72.8%) and 5-FUþINFa (70.9%).
However, no differences were seen after 5 years (Table 5,
Figure 4A). The addition of FA tended to an improved OS
in stage II, whereas no effects were observed in stage III disease
(Table 5, Figure 4B+C). Overall survival was influenced by
UICC substage, tumour grading, and resection type (Table 5,
Figure 4D–F).
DISCUSSION
Adjuvant chemoradiotherapy of locally advanced rectal cancer was
established based on three trials, including 104 (Gastrointestinal
Tumor Study Group, 1985), 204 (Krook et al, 1991), and 555
patients (Fisher et al, 1988). Our trial design was based on the
results of these studies not allowing a ‘surgery-only’ arm. The main
problem of the study was patient recruitment. Nevertheless,
duration and time of recruitment are comparable to other
European rectal cancer trials launched in the early 1990s
(Sauer et al, 2004; Bosset et al, 2006; Ge ´rard et al, 2006). The
German ARO-CAO-AIO-94 study compared pre- vs postoperative
chemoradiotherapy (Sauer et al, 2004), and the two French trials
compared pre-operative radiotherapy with chemoradiotherapy
with or without postoperative chemotherapy (Bosset et al, 2006;
Ge ´rard et al, 2006). Two trials initiated in the United States in the
early 1990s comparing pre-operative chemoradiotherapy with
standard, postoperative chemoradiotherapy by the RTOG
(trial 94-01) and the National Surgical Adjuvant Breast and Bowel
Project (protocol R-03) were closed prematurely owing to low
enrolment (Hyams et al, 1997). Trials starting in the later 1990s
compared pre-operative short-course radiotherapy vs TME surgery
alone (Peeters et al, 2007) or vs postoperative selective chemo-
radiotherapy (Sebag-Montefiore et al, 2009) or pre-operative
short-course radiotherapy vs chemoradiotherapy applying TME
surgery (Bujko et al, 2006). With the exception of the Swedish
Rectal Cancer Trial (1997), rectal cancer trials involving multi-
modal treatment revealed improvement of local control without
benefit for prognosis (Sauer et al, 2004; Bosset et al, 2006; Bujko
et al, 2006; Ge ´rard et al, 2006; Peeters et al, 2007; Sebag-Montefiore
et al, 2009).
In the area of TME surgery, prognosis of patients with locally
advanced rectal cancer primarily depends on the occurrence
of distant metastases. No study could show an improvement of
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Figure 3 Recurrence-free survival according to: (A) treatment for all stages; (B) treatment of stage II (pT3/4pN0); (C) treatment of stage III
(pT1-4pNpos); (D) UICC stage II (pT3/4pN0), and substages IIIa (pT1/2pN1), IIIb (pT3/4pN1), and IIIc (pT1-4pN2); (E) tumour grading (G1þ2 vs G3);
and (F) type of resection: anterior resection (AR), abdominoperineal resection (APR), and resection type unknown (UNK). AR included nine Hartmann
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to standard 5-FU (de Gramont and Haller, 2008). Our study aimed
to improve prognosis by modulating 5-FU by either addition of FA
or INFa. In parallel, we carried out an equivalent study in colon
cancer, except radiation including 855 patients (Link et al, 2005).
Similar to our colon cancer study, INFa increased toxicity in rectal
cancer, too, without survival benefit. The effectiveness of combin-
ing 5-FU with FA in colon cancer is generally accepted and was
confirmed in our colon trial increasing the 5-year OS rate from
61 to 72% using the same drug administration and protocol design
(Link et al, 2005). More than 90% of patients with stage III colon
cancer were included. In this study, not a trend of benefit was
observed in node-positive (stage III) rectal cancer. However, there
seemed to be a benefit of FA addition in stage II cutting LR rate by
half and enhancing OS by almost 10 points of percentage (82.1 vs
72.7%) compared with 5-FU. A pooled analysis of Scandinavian
patients comparing surgery only with postoperative adjuvant
5-FU-based chemotherapy in rectal cancer showed a similar trend.
Patients with stage II seemed to benefit, whereas there was no
effect of adjuvant treatment compared with surgery alone in stage
III (Glimelius et al, 2005). A subgroup analysis of EORTC Trial
22921 comparing pre-operative (chemo)radiotherapy with or
without postoperative chemotherapy in a 2 2 factorial design
revealed that responders (ypT0–2) seemed to benefit from
adjuvant chemotherapy in contrast to non-responders (ypT3–4)
(Collette et al, 2007). These observations suggest that especially
non-metastasised and radiosensitive tumours may benefit from
adjuvant 5-FU treatment with the addition of FA, whereas non-
responding and lymph node-positive tumour may not.
On the basis of this observation in stage II of our study that the
reduction of LR was associated with an improvement of RFS and
OS and the ineffectiveness of FA in stage III, some assumptions
can be made. First, the addition of FA (200mgm
 2) may enhance
the effect of 5-FU as a radiosensitiser to improve local control.
Second, the addition of FA may be ineffective to avoid recurrence
at a stage of rectal cancer at which metastatic spread is already
present in lymph nodes. Third, chemosensitivity of rectal cancer
may differ from that of colon cancer. This is supported by
comparisons with colon cancer trials (Glimelius et al, 2005; Link
et al, 2005) and other trials failing to show an improvement of
adjuvant 5-FU monotherapy in rectal cancer (QUASAR Collabora-
tive Group, 2000; Tepper et al, 2002; Dahl et al, 2009). In addition,
new combinations, which also showed effectiveness in colon
cancer treatment, failed to show any benefit in rectal cancer so
far (Glynne-Jones et al, 2010; Weiss et al, 2010). The German
CAO/ARO/AIO-04 rectal cancer trial comparing standard 5-FU
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Figure 4 Overall survival according to: (A) treatment for all stages. 5-Fluorouracil vs 5-FUþFA: log-rank test, P¼0.461; (B) treatment of stage II
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including oxaliplatin in the pre- and postoperative setting (Ro ¨del
and Sauer, 2007), was recently closed for recruitment. However, no
differences in the rate of pathological complete response to
neoadjuvant therapy as a surrogate marker for overall prognosis
were reported so far. The effects on distant metastasis and final
outcome render evaluation after sufficient follow-up time in a few
years for this and other ongoing European and United States trials.
The duration of adjuvant chemotherapy in our trial was
12 months. All patients received oral levamisol. Presently, a
duration of 6–8 months is recommended with omission of
levamisol. These recommendations are mainly based on results
obtained from colon cancer trials showing no difference in
outcome omitting levamisol and shortening the duration of
chemotherapy. The four-arm INT-0089 trial, including patients
with high-risk stage II and stage III colon cancer, revealed no
significant difference between adjuvant therapy with 5-FUþFA
(low dose, 20mgm
 2 or high dose, 500mgm
 2) for 7–8 months
and the 12-month 5-FUþLEV standard and an increase in the 5-
year OS rate from 63% (12-month 5-FUþLEV) to 67% for 7–8
months 5-FUþLEVþFA (low dose) (Haller et al, 1998). The
NCCTG/NCIC trial (O’Connell et al, 1998), including 915 similarly
staged patients, displayed 5-year OS rates of 64% for 12-month
5-FUþLEV, of 61% for 12-month 5-FUþLEVþFA, of 69% for
6-month treatment with 5-FUþFA, and of 59% for 6-month
treatment with 5-FUþLEV. Except the two 6-month treatment
arms, the differences between the treatment arms were not
significant. On the basis of the results, a 6- to 8-month adjuvant
treatment seemed to be equivalent to a 12-month 5-FUþLEV
treatment after the addition of FA. Furthermore, omission of LEV
seemed to be justified without compromising the survival benefit
in colon cancer.
Attention has be drawn to a variety of additional anatomical and
surgical factors influencing the outcome of rectal cancer. The
tumour distance from the anal verge seems of great importance as
shown in our study as well. As a result, patients with low rectal
cancer undergoing an APR had a 63% higher LR rate than patients
undergoing an AR in our and other studies (Wibe et al, 2002;
den Dulk et al, 2009). Localisation of the tumour in the rectum
may be another essential prognostic factor. To achieve a complete
resection with negative circumferential resection margins, it is
important that the tumour is covered with mesorectal fatty tissue
(Heald et al, 2004; Nagtegaal and Quirke, 2008). The mesorectum is
thinned out in the lower parts, especially in the front (Heald et al,
2004). Moreover, the individual surgeon may be also another
important prognosticator (Martling et al, 2000). All these factors
and the combination with radiotherapy may dilute the positive
effect of 5-FU modulation by FA in rectal cancer, which seems so
obvious in colon cancer.
In summary, we could not show a benefit of modulating 5-FU
with either FA or INFa in adjuvant chemoradiotherapy of locally
advanced rectal cancer despite a tendency in improved 3-year
survival. Nevertheless, our results point out to a potential long-
term benefit of FA in stage II disease. Therefore, in our opinion,
this protocol can be recommended for adjuvant chemoradio-
therapy of stage II disease. Owing to a reduction in LR, we
conclude that this effect may be due to increased efficacy of
chemoradiotherapy. In the future, this protocol may be recom-
mended for patients not having received neoadjuvant treatment
being diagnosed with a pT3c/dpN0 tumour or with a small CRM
(o2mm). Patients with pT3a/bpN0 or a large CRM (42mm) may
undergo observation. The effect of adjuvant treatment, even 5-FU
monotherapy, after neoadjuvant chemoradiotherapy and high
quality of surgery renders re-evaluation.
Our study further confirmed important prognostic factors like
grading, type of resection, and UICC substage (Gunderson et al,
2002). In view of the efficacy of our FA protocol in colon cancer,
we further conclude that rectal cancer may be a separate entity
with different chemosensitivity. This is supported by numerous
observations of differences in genetic alterations or target gene
expression like microsatellite instability or expression of thymi-
dylate synthase (Kornmann et al, 2003; Allen and Johnston, 2005;
Wilson et al, 2007).
As all attempts to optimise and develop new combinations for
chemotherapy of rectal cancer have failed so far and no really
promising additional multimodal treatment options are under
evaluation at present, it seems important to focus on approaches
minimising over-treatment. For example, accurate pre-therapeutic
MRI-based local staging may better identify patients that can profit
from neoadjuvant treatment based on the CRM. In conjunction
with additional individual prognostic markers like grading,
tumour location, and tumour substaging, this may help to reduce
the need for multimodal strategies. Future trials should therefore
aim at optimising available multimodal options for high-risk
subgroups, thereby reducing the overall number of patients
undergoing multimodal treatment. A recent survey asking
laypersons about their preferred treatment choices further would
support this strategy (Kornmann et al, 2008). This may save
toxicity and increase quality of life without hampering prognosis.
These efforts may eventually help to individualise and optimise
multimodal treatment of locally advanced rectal cancer in the
future.
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